ライフサイエンスコーパス: continued treatment

1 ment were the most likely to gain BMD during continued treatment.

2 eginning IFN therapy or later as a result of continued treatment.

3 ered nearly normal blood counts, even during continued treatment.

4 hrombocytopenia completely resolved, despite continued treatment.

5 e, and all grades declined in frequency with continued treatment.

6 ients are likely to remain in remission with continued treatment.

7 weight regain over time is common even with continued treatment.

8 Of these, 12 of 15 (80%) continued treatment.

9 ne of whom died), and 9 of 12 patients (75%) continued treatment.

10 tions during the previous 12 months, despite continued treatment.

11 the conventional continuation strategy group continued treatment.

12 et existing drugs lose their efficacy during continued treatment.

13 st likely to accrue the largest benefit from continued treatment.

14 ity in these mice returned to normal despite continued treatment.

15 with a delayed onset and resolution despite continued treatment.

16 ation for at least 1 month; control patients continued treatment.

17 onitor response, tolerance, and the need for continued treatment.

18 d to autologous stem cell transplantation or continued treatment.

19 discontinued treatment and 4.9 for women who continued treatment.

20 ponse at first assessment, 25% improved with continued treatment.

21 cutaneous atrophy followed by resistance to continued treatment.

22 In such cases, there is no benefit to continued treatment.

23 s discontinued, whereas 24 patients required continued treatment.

24 a milepost at which to reassess the need for continued treatment.

25 ts who survived at least 6 months was 88% on continued treatment.

26 often require care at a regional center for continued treatment after resuscitation, but many do not

27 hypertriglyceridemia in 30% of patients who continued treatment along with antilipid therapy, and mi

28 of 67 patients in the momelotinib group who continued treatment and 15 (50%) of 30 in the danazol gr

29 score change at 6 months and 18 months after continued treatment and changes in neurocognitive domain

30 te Clinical Score (ADCOMS) at 12 months with continued treatment and follow-up out to 18 months.

31 The study began in 1997, with continued treatment and follow-up through June 1, 2011.

32 ommon daily multivitamin, began in 1997 with continued treatment and follow-up through June 1, 2011.

33 etween scans, inpatient individuals with HUD continued treatment and related clinical interventions.

34 stopped treatment, switched practitioner, or continued treatment), and whether participation of a spe

35 positive score at 16 weeks should encourage continued treatment, and a negative score should prompt

36 sk and intermediate-risk patients with HF as continued treatment, and more precise risk stratificatio

37 th network who initiated hydroxychloroquine, continued treatment, and underwent retinopathy screening

38 ithdrawal, even if the perceived benefits of continued treatment are not clear.

39 With continued treatment, at month 24, patients with DME with

40 of diagnosis, and the number of patients who continued treatment beyond 1 year, switched treatments,

41 lowing hospitalization discharge for VTE and continued treatment beyond 90 days.

42 group analysis, a proportion of patients who continued treatment beyond RECIST-defined first progress

43 Forty-three patients (73%) continued treatment beyond six cycles; the median cumula

44 t trimester and in 26.1% of the 92 women who continued treatment beyond the first trimester.

45 Two of these participants continued treatment beyond the original 24 cycles due to

46 develop clinically meaningful responses with continued treatment can be assessed.

47 in FEV1, -5.28% [CI, -10.03% to -0.54%]) or continued treatment (change in FEV1, 1.07% [CI, -3.3% to

48 cy resulting in a live birth as patients who continued treatment; conservative methods assumed no liv

49 distinct weight maintenance approaches vs no continued treatment control following standard family-ba

50 For women receiving continued treatment, cumulative success rates are a more

51 l setting (ie, the effect as if participants continued treatment despite adverse events), and 19 (79%

52 le taking OUD treatment before pregnancy and continued treatment during pregnancy.

53 The protocol was later amended to allow for continued treatment during the second year.

54 had type 2 diabetes records, which revealed continued treatment during the war period.

55 In patients who continued treatment for 24 weeks and could also use stab

56 from December 2014 to December 2016 and who continued treatment for 3 years.

57 astrointestinal intolerance, and 15 patients continued treatment for 6 +/- 1 year.

58 ts with objective response or stable disease continued treatment for a maximum of four courses or unt

59 had an objective response or stable disease continued treatment for a maximum of six courses.

60 s, suggesting the need for more intensive or continued treatment for a sizable proportion of youths w

61 th no detectable HCV RNA in serum at week 20 continued treatment for a total of 48 weeks and were the

62 In total, 29 patients continued treatment for at least 1 year and 18 patients

63 e ART treatment before 7 days of age and who continued treatment for at least 96 weeks.

64 Continued treatment for depression among treatment-resis

65 within the earliest weeks of the disease and continued treatment for more than 10 years.

66 reatment during the following 60 days, or 3) continued treatment for more than 90 days after treatmen

67 eous coronary intervention (PCI) followed by continued treatment for one year.

68 e associated with worse vision outcomes, and continued treatment for persistent HEs in the absence of

69 who had objective response or stable disease continued treatment for six courses.

70 who have few treatment options and who need continued treatment for tuberous sclerosis complex and i

71 tiretroviral therapy may derive benefit from continued treatment for two reasons.

72 5 mg/day i.v. within 48 hr of transplant and continued treatment for up to 14 days; ATG was stopped o

73 ts with a partial response or stable disease continued treatment for up to 17 cycles.

74 With continued treatment for up to 48 or 72 hours, more than

75 50) and VP100 (VP100-VP250) participants and continued treatment for VP250 participants (total = 130

76 50) and VP100 (VP100-VP250) participants and continued treatment for VP250 participants (total = 130

77 After 6 months, patients in the continued treatment group had treatment withdrawn by the

78 h care, 11,450 initiated treatment, and 6554 continued treatment >1 year.

79 those who discontinued treatment, those who continued treatment had markedly lower rates of recurren

80 All 10 patients who continued treatment had stable disease at 3 mo.

81 n days 1 and 15 of the open-label period) or continued treatment if assigned inebilizumab (receiving

82 Grace periods (periods assuming continued treatment impact after days' supply exhaustion

83 dult deficits in social interaction, whereas continued treatment into adulthood also significantly re

84 sporine can also improve control in MCD, but continued treatment is often needed to maintain remissio

85 However, frequent, continued treatment is required to generate and maintain

86 ffects on the CNS of infected cats, although continued treatment is required to maintain unimpaired C

87 e episodes, the illness is still active, and continued treatment is strongly recommended.

88 Continued treatment led to overall sustained benefits, b

89 ugh DTG initially reduced virus replication, continued treatment led to the emergence of a variety of

90 o substantial regain of lost weight, whereas continued treatment maintained and augmented initial wei

91 macy and multimorbidity when the benefits of continued treatment may not outweigh the harms.

92 These findings suggest that continued treatment may result in greater vision improve

93 a chronic or recurrent course that requires continued treatment, meaning that patients must be provi

94 In addition, after continued treatment of JEV with Cur-CQDs, a mutant strai

95 positively related to age and income, while continued treatment of preexisting cases was positively

96 determine whether these effects persist with continued treatment or after discontinuation of the drug

97 maintenance and durability of response with continued treatment over time.

98 ) points in 30 video visit nonresponders who continued treatment (P = .58).

99 With continued treatment, patients with inconsistently positi

100 in less certain, but limited experience with continued treatment suggests this approach must be under

101 However, toxicity was a concern and without continued treatment the efficacy disappeared by 24 month

102 the incidence of gout flares diminished with continued treatment, the overall incidence during weeks

103 at week 4 was clearly high enough to justify continued treatment; the rate for unimproved patients at

104 ined responses to IFN and allow the value of continued treatment to be determined early in the course

105 Patients continued treatment to progression or excessive toxic ef

106 Twenty continued treatment to week 8, and 15 (75%) required an

107 Despite continued treatment, tumors eventually become insensitiv

108 ts with objective response or stable disease continued treatment until disease progression or unaccep

109 Patients continued treatment until disease progression, unaccepta

110 se with objective response or stable disease continued treatment until disease progression.

111 Of 49 patients treated, 47 (95.9%) continued treatment until month 6.

112 However, continued treatment until P8 or P10 did not prevent the

113 8 weeks of treatment; patients who responded continued treatment until they experienced tumor progres

114 Patients continued treatment until treatment failure.

115 Responding and stable patients continued treatment until tumor progression or for a rec

116 739 patients started treatment; 716 patients continued treatment up to week 24.

117 ed on quetiapine plus lithium or divalproex, continued treatment was associated with a significant ri

118 ion dual antiplatelet therapy (</=6 months), continued treatment was not associated with a difference

119 s on single-dose treatment and 10 studies on continued treatment were included.

120 Animals that continued treatment with 10 mg/kg/day in three additiona

121 high-dose clopidogrel, and those without HPR continued treatment with 75 mg of clopidogrel.

122 Three days later, patients continued treatment with 80 mg/kg hydroxyurea orally eve

123 risk of relapse in depressive disorder, and continued treatment with antidepressants would benefit m

124 We aimed to assess whether continued treatment with antipsychotics in people with A

125 s benefit emerged early and persisted during continued treatment with background antiplatelet therapi

126 , 345 entered the 24-week extension, and 296 continued treatment with belimumab in the long-term cont

127 corticoid tapering were randomly assigned to continued treatment with canakinumab or to placebo.

128 ents after asparaginase, which may be due to continued treatment with corticosteroids.

129 During 2.3 years of continued treatment with dabigatran after RE-LY, there w

130 may wish to periodically assess the need for continued treatment with daily suppressive antiviral che

131 with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with c

132 Continued treatment with doxycycline caused progressive

133 inferior to the mean change for patients who continued treatment with epoetin (-0.75 g/L, -2.26 to 0.

134 Only 4.3% of study participants continued treatment with fenofibrate following completio

135 Continued treatment with fluoxetine in patients with bul

136 persistence of BCR/ABL+ progenitors despite continued treatment with imatinib mesylate.

137 from transplant centres after HCT requiring continued treatment with immunosuppressive drugs that in

138 is post hoc analysis evaluated the effect of continued treatment with inhaled treprostinil on the fre

139 ed the long-term effectiveness and safety of continued treatment with intravenous pamidronate infusio

140 ondary to renal insufficiency and eventually continued treatment with itraconazole cyclodextrin, 100

141 of participants with lenacapavir resistance, continued treatment with lenacapavir + active OBR led to

142 340 patients continued treatment with lumacaftor 400 mg every 12 h/iv

143 f less than 8% and were randomly assigned to continued treatment with metformin alone or to metformin

144 Continued treatment with methylphenidate remains effecti

145 ssion were then randomly assigned to receive continued treatment with myeloablative chemotherapy, tot

146 The findings suggest that continued treatment with naltrexone may be beneficial fo

147 or neurotrophins or their receptors; and (2) continued treatment with neurotrophins fails to achieve

148 er these conditions is strictly dependent on continued treatment with NGF.

149 seline measures, patients were randomized to continued treatment with nifedipine or an equivalent dos

150 Black adults who smoke relative to those who continued treatment with NP.

151 release once every 28 days for 24 weeks, or continued treatment with octreotide or lanreotide (activ

152 ide provides superior efficacy compared with continued treatment with octreotide or lanreotide, and c

153 Three responding patients continued treatment with rhuMAbVEGF and chemotherapy, re

154 Continued treatment with sertraline yielded lower PTSD r

155 articipants were offered the opportunity for continued treatment with the opiate antagonist, naltrexo

156 The remaining 2 CD and 8 UC patients continued treatment with the same biological agent with

157 of metformin or sulfonylurea monotherapy who continued treatment with their glucose-lowering medicati

158 Continued treatment with thienopyridine, as compared wit

159 The effect of continued treatment with tirzepatide on maintaining init

160 Continued treatment with TRP antagonists blocked the dev

161 ect was observed for PRM-151 in patients who continued treatment, with a decline in percentage of pre

162 nacceptable serious adverse events (safety), continued treatment without adverse event requiring dose

163 persistence with P2Y12 inhibitor (defined as continued treatment without gap in use >=30 days) and MA

164 with poor initial response may benefit from continued treatment without switching to another drug.